scholarly journals Alzheimer’s Disease – The Past, the Present and the Future

2017 ◽  
Vol 6 (1) ◽  
pp. 1 ◽  
Author(s):  
Benson Opare Asamoah Botchway
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Past ◽  
The Future

Application of Carbon Nanotubes in Drug Delivery of Non-Cancerous Diseases: A Review

2020 ◽  
Vol 26 ◽  
Author(s):  
Shahebaaz Khan ◽  
Puja Jawlikar ◽  
Swaroop Lahoti ◽  
Omprakash Bhusnure ◽  
Sohan Chitlange ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Alzheimer’S Disease ◽  
Carbon Nanotubes ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Pulmonary Diseases ◽  
Cancer Disease ◽  
The Past ◽  
The Future ◽  
Asthma Patients

: Carbon nanotubes (CNT) are the allotropes of carbon in nanosize rendering them popular in the field of medicines. These nano-based technologies are gaining interest in the treatment of disease which was previously seemed to be impossible for treating. CNT gained significance in the treatment of the majority of disorders such as Malaria, Alzheimer’s disease, Infectious disease, Asthma. Patients responsiveness has increased in cardiovascular, pulmonary diseases. To date, the number of reviews available in the literature covering applications of CNT in the cancer disease. However, the purpose of this review is to focus on the use of carbon nanotubes in drug delivery of non-cancerous disease. The novelty of this review is it is focused on the applicability of CNT in the various non-cancerous diseases. Detailed information gathered from the past literature can guide and encourage researchers to explore the applicability of CNT in various non-cancerous diseases in the future.

scholarly journals The Past and the Future of Alzheimer’s Disease Fluid Biomarkers1

2018 ◽  
Vol 62 (3) ◽  
pp. 1125-1140 ◽  
Author(s):  
Kaj Blennow ◽  
Henrik Zetterberg
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Past ◽  
The Future

scholarly journals STRENGTH IN AGE: HARNESSING THE BENEFITS OF NIA’S 45 YEARS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S437-S438
Author(s):  
Marie A Bernard ◽  
Richard Hodes ◽  
Robin A Barr
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Panel Discussion ◽  
National Institutes Of Health ◽  
Special Populations ◽  
Older Individuals ◽  
Aging Research ◽  
The Past ◽  
Age Related ◽  
The Future

Abstract The National Institute on Aging at the National Institutes of Health was established in 1974 with a mission to support and conduct research on aging processes, age-related diseases, and special problems and needs of the aged. Shortly thereafter, the Institute was designated by Congress as the lead research agency in Alzheimer’s disease. During this symposium, NIA’s scientific leadership will reflect on major accomplishments to improve the health of older individuals over the past 45 years and look to the future of the NIA and aging research. This symposium will describe progress led by NIA’s extramural divisions, the intramural program, and the Office of Special Populations. A brief panel discussion will ensue, followed by an informal reception and opportunities for networking in celebration of NIA’s 45 years

Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease

2020 ◽  
Vol 10 (3) ◽  
pp. 228-247
Author(s):  
Niloufar Choubdar ◽  
Sara Avizheh
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Polymeric Nanoparticles ◽  
Biological Fluids ◽  
Delivery Systems ◽  
Original Research ◽  
Sustained Drug Release ◽  
The Past ◽  
Site Of Action ◽  
Therapeutic Compound

Alzheimer’s Disease (AD) is one of the most common forms of dementia affecting over 46 million people, according to AD International. Over the past few decades, there has been considerable interest in developing nanomedicines. Using nanocarriers, the therapeutic compound could be delivered to the site of action where it gets accumulated. This accumulation, therefore, reduces the required doses for therapy. Alternatively, using nanocarriers decreases the side effects. Nanotechnology has had a great contribution in developing Drug Delivery Systems (DDS). These DDS could function as reservoirs for sustained drug release or control the pharmacokinetics and biodistribution of the drugs. In the current review, we have collected 38 original research articles using nanotechnology as DDS for the clinically used cholinesterase inhibitor drugs donepezil (DPZ), Rivastigmine (Riv), and galantamine (Gal) used for AD treatment from 2002 to 2017 from Scopus and PubMed databases. Regarding DDS used for DPZ, most of the research in recent years dealt with polymeric nanoparticles (NPs) including Poly-D, L-Lactide-Co-Glycolide (PLGA), and chitosans (CHs), then Liposomes (LPs), nanogels, and natural products, respectively. In terms of Riv most of the research performed was focused on polymeric NPs including PLGA, polylactic acid (PLA), Poly-Ε-Caprolactone (PCL), poly-alkyl-cyanoacrylates, CH, gelatin and then LPs. The highest application of NPs in regard to Gal was related to modified LPs and polymeric NPs. Polymeric NPs demonstrate safety, higher stability in biological fluids and against enzymatic metabolism, biocompatibility, bioavailability, and improved encapsulation efficacy. LPs, another major delivery system used, demonstrate biocompatibility, ease of surface modification, and amphiphilic nature.

Visual imagery: The past and future as seen by patients with Alzheimer’s disease

2019 ◽  
Vol 68 ◽  
pp. 12-22 ◽  
Author(s):  
Mohamad El Haj ◽  
Ahmed A. Moustafa ◽  
Karim Gallouj ◽  
Frédérique Robin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Visual Imagery ◽  
The Past

scholarly journals Alzheimer’s Disease: Current and Future Treatments. A Review

2014 ◽  
Vol 2 (2) ◽  
pp. 56-63
Author(s):  
Evelyn Chou
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Neurodegenerative Disorder ◽  
Nmda Antagonists ◽  
Disease Modifying Drugs ◽  
Plaque Deposition ◽  
The Future ◽  
Disease Modifying ◽  
Future Treatments

Alzheimer’s disease (AD) is a currently incurable neurodegenerative disorder whose treatment poses a big challenge. Proposed causes of AD include the cholinergic, amyloid and tau hypotheses. Current therapeutic treatments have been aimed at dealing with the neurotransmitter imbalance. These include cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) antagonists. However, current therapeutics have been unable to halt AD progression. Much research has gone into the development of disease-modifying drugs to interfere with the course of the disease. Approaches include secretase inhibition and immunotherapy aimed at reducing plaque deposition. However, these have not been successful in curing AD as yet. It is believed that the main reason why therapeutics have failed to work is that treatment begins too late in the course of the disease. The future of AD treatment thus appears to lie with prevention rather than cure. In this article, current therapeutics and, from there, the future of AD treatment are discussed.

Sign in / Sign up

Export Citation Format

Share Document